Natco Pharma Share Price in Focus; Completes 35.75% Stake Buy in Adcock Ingram

Natco Pharma has completed the acquisition of a 35.75% stake in Adcock Ingram Holdings, a pharmaceutical company based in South Africa. The deal is valued at about $226 million, or roughly ZAR 4 billion, as per the company’s filing.

Adcock Ingram Delisted from JSE

Following the completion of the transaction, Adcock Ingram has been delisted from the Johannesburg Stock Exchange (JSE) effective November 11, 2025. The delisting was part of the acquisition process that had been underway for several months.

In July 2025, Natco Pharma proposed to buy shares held by Adcock Ingram’s minority shareholders at ZAR 75 per share ($4.36). The offer received approval in October 2025, allowing the transaction to move forward.

About Adcock Ingram

Founded in 1891, Adcock Ingram is one of South Africa’s oldest pharmaceutical firms. It manufactures and markets a range of healthcare products under well-known names such as Panado, Myprodol, Epi-Max, Citro-soda, and Allergex. The company has been a part of the region’s healthcare system for over 135 years.

With this acquisition, Natco Pharma has gained a foothold in the South African pharmaceutical market. The company said the process aligns with its plan to expand operations in international markets.

Read More: Cipla, Natco Pharma, and Other Firms Win Several Drug Supply Bids in China!

Natco Pharma Share Price Performance 

As of November 13, 2025, 10:21 am, Natco Pharma share price was trading at ₹826.85, a 0.55% increase from the previous closing price.

Conclusion

The acquisition gives Natco Pharma a direct entry into South Africa’s pharmaceutical sector. The transaction also concludes the delisting of Adcock Ingram from the Johannesburg Stock Exchange after shareholder approval earlier this year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.